

## **PRODUCT INFORMATION**

BGB-A317;BGB

**Common Name** A317;TEVIMBRA;Tilelizumab;VDT-482;VDT

482; VDT482

**Synonyms** PD1;PD-1;CD279;SLEB2;hPD-1;hPD-I;hSLE1

**Applications** Flow Cyt

Recommended

Flow Cyt 1:100 **Dilutions** 

Formulation & Reconstitution

Liquid PBS with 0.05% Proclin300, 1% BSA

**Host Species** N/A IgG4 IgG type Reactivity Human PD-1 **Target Uniprot ID** Q15116

PE-conjugated Anti-PD-1(tislelizumab biosimilar) **Description** 

mAb

**Delivery** 6-8 weeks

Storage & Shipping Store at 2°C-8°C for 6 months

Research grade biosimilar. Not for use in

therapeutic or diagnostic procedures for humans **Background** 

or animals.

Research use only **Usage** 

Conjugate PE-conjugated

All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under

Email: info@dimabio.com Website: www.dimabio.com

patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to **DIMA Disclaimer** 

ensure no IP infringement.

